LRIG1 Improves Chemosensitivity Through Inhibition of BCL-2 and MnSOD in Glioblastoma

Cell Biochemistry and Biophysics

Volumn 71, Issue 1, 2015, Pages 27-33

  Ding, Jianjun ^a,b   Liu, Baohui ^a   He, Yi ^b   Yuan, Xianhou ^a   Tian, Daofeng ^a   Ji, Baowei ^a   Wang, Long ^a   Wu, Liquan ^a   Dong, Huimin ^a   Wang, Junmin ^a   Zhu, Xiaonan ^a   Cai, Qiang ^a   Zhang, Shenqi ^a   Chen, Qianxue ^a  

^a WUHAN UNIVERSITY   (China)

^b The Second People's Hospital of Shenzhen   (China)

Author keywords

B cell lymphoma 2 (BCL 2); Chemosensitivity; Leucine rich repeats and immunoglobulin like domains 1 (LRIG1); Manganese superoxide dismutase (MnSOD)

Indexed keywords

DACARBAZINE; LRIG1 PROTEIN, HUMAN; MANGANESE SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; PROTEIN BCL 2; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; TEMOZOLOMIDE;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; CELL LINE, TUMOR; DACARBAZINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84925497863     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0139-6     Document Type: Article

References (32)

1. Nikiforova, M. N., & Hamilton, R. L. (2011). Molecular diagnostics of gliomas. Archives of Pathology and Laboratory Medicine,135(5), 558–568.
2. Nikaki, A., Piperi, C., & Papavassiliou, A. G. (2012). Role of microRNAs in gliomagenesis: Targeting miRNAs in glioblastoma multiforme therapy. Expert Opinion on Investigational Drugs,21(10), 1475–1488.
3. Spinelli, G. P., et al. (2012). Chemotherapy and target therapy in the management of adult high-grade gliomas. Current Cancer Drug Targets,12(8), 1016–1031.
4. Sun, S., et al. (2012). Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. Journal of Neuro-Oncology,109(3), 467–475.
5. Alla, V., et al. (2012). E2F1 confers anticancer drug resistance by targeting ABC transporter family members and BCL-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle,11(16), 3067–3078.
6. Greaves, W., et al. (2012). Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. Journal of Hematology & Oncology,5, 47.
7. Herraez, E., et al. (2012). Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Molecular Pharmaceutics,9(9), 2565–2576.
8. Michalak, K., & Wesolowska, O. (2012). Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins. Anti-Cancer Agents in Medicinal Chemistry,12(8), 880–890.
9. Minami, T., et al. (2012). HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. Molecular Cancer Therapeutics,11(4), 830–841.
10. Tian, C., et al. (2012). Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study. Gynecologic Oncology,124(3), 575–581.
11. Nilsson, J., et al. (2001). Cloning, characterization, and expression of human LIG1. Biochemical and Biophysical Research Communications,284(5), 1155–1161.
12. Holmlund, C., et al. (2004). Characterization and tissue-specific expression of human LRIG2. Gene,332, 35–43.
13. Guo, D., et al. (2004). The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics,84(1), 157–165.
14. Suzuki, Y., et al. (1996). cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. Journal of Biological Chemistry,271(37), 22522–22527.
15. Yi, W., et al. (2009). Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age. Clinical Neuropathology,28(1), 21–27.
16. Liu, B., Chen, Q., Tian, D., Wu, L., Wang, J., Cai, Q., et al. (2011). Increased leucine-rich repeats and immunoglobulin-like domains 1 expression enhances chemosensitivity. Neural Regeneration Research,6(32), 2516–2520.
17. Johnson, D. R., & Chang, S. M. (2012). Recent medical management of glioblastoma. Advances in Experimental Medicine and Biology,746, 26–40.
18. Higgins, C. F. (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature,446(7137), 749–757.
19. Jennings, M. T., & Iyengar, S. (2001). The molecular genetics of therapeutic resistance in malignant astrocytomas. The American Journal of Pharmacogenomics,1(2), 93–99.
20. Stupp, R., et al. (2007). Chemoradiotherapy in malignant glioma: Standard of care and future directions. Journal of Clinical Oncology,25(26), 4127–4136.
21. Lu, C., & Shervington, A. (2008). Chemoresistance in gliomas. Molecular and Cellular Biochemistry,312(1–2), 71–80.
22. Wang, X., et al. (2012). LRIG1 enhances cisplatin sensitivity of glioma cell lines. Oncology Research,20(5–6), 205–211.
23. Desjardins, A., Reardon, D. A., & Vredenburgh, J. J. (2009). Current available therapies and future directions in the treatment of malignant gliomas. Biologics,3, 15–25.
24. Johansson, M., et al. (2013). The soluble form of the tumor suppressor LRIG1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro-Oncology,15(9), 1200–1211.
25. Yang, C. H., et al. (2013). Pulsed radiofrequency treatment attenuates increases in spinal excitatory amino acid release in rats with adjuvant-induced mechanical allodynia. NeuroReport,24(8), 431–436.
26. Yi, W., et al. (2011). Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Experimental Cell Research,317(4), 504–512.
27. Ye, F., et al. (2009). Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. Journal of Neuro-Oncology,94(2), 183–194.
28. Stutz, M. A., et al. (2008). LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene,27(43), 5741–5752.
29. Griguer, C. E., & Oliva, C. R. (2011). Bioenergetics pathways and therapeutic resistance in gliomas: Emerging role of mitochondria. Current Pharmaceutical Design,17(23), 2421–2427.
30. Decleves, X., et al. (2006). Role of ABC transporters in the chemoresistance of human gliomas. Current Cancer Drug Targets,6(5), 433–445.
31. Sodani, K., et al. (2012). GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochemical Pharmacology,83(12), 1613–1622.
32. Ng, W. H., et al. (2009). Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas. Journal of Clinical Neuroscience,16(3), 427–436.